Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy W Jones

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
International Journal of Geriatric Psychiatry|September 16, 2003
Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?Roy W Jones
Alzheimer'S Research & Therapy|September 15, 2010
Dimebon disappointmentRoy W Jones
Clinical Medicine (London, England)|November 7, 2003
The dementiasRoy W Jones
Age and Ageing|July 1, 2004
Dementia, postcode prescribing and NICERoy W Jones
Clinical Medicine (London, England)|March 17, 2011
Drug treatment for people with dementiaRoy W Jones
Applied Neuropsychology|December 15, 2010
Brief communication: cognitive rehabilitation of executive functioning in a case of craniopharyngiomaClaudia Metzler-Baddeley, Roy W Jones
Drugs & Aging|July 21, 2004
Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspectiveRoy W Jones, Paul McCrone, Chantal Guilhaume
BMJ Open|January 10, 2013
Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort studyCarlos Martinez, Roy W Jones, Stephan Rietbrock
Age and Ageing|June 26, 2007
Can people with mild to moderate dementia provide reliable answers about their quality of life?Richard Trigg, Roy W Jones, Suzanne M Skevington
The Gerontologist|January 15, 2008
How can we best assess the quality of life of people with dementia? the Bath Assessment of Subjective Quality of Life in Dementia (BASQID)Richard Trigg, Suzanne M Skevington, Roy W Jones
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Geriatric Psychiatry|September 16, 2003
Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?Roy W Jones
Alzheimer'S Research & Therapy|September 15, 2010
Dimebon disappointmentRoy W Jones
Clinical Medicine (London, England)|November 7, 2003
The dementiasRoy W Jones
Age and Ageing|July 1, 2004
Dementia, postcode prescribing and NICERoy W Jones
Clinical Medicine (London, England)|March 17, 2011
Drug treatment for people with dementiaRoy W Jones
Applied Neuropsychology|December 15, 2010
Brief communication: cognitive rehabilitation of executive functioning in a case of craniopharyngiomaClaudia Metzler-Baddeley, Roy W Jones
Drugs & Aging|July 21, 2004
Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspectiveRoy W Jones, Paul McCrone, Chantal Guilhaume
BMJ Open|January 10, 2013
Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort studyCarlos Martinez, Roy W Jones, Stephan Rietbrock
Age and Ageing|June 26, 2007
Can people with mild to moderate dementia provide reliable answers about their quality of life?Richard Trigg, Roy W Jones, Suzanne M Skevington
The Gerontologist|January 15, 2008
How can we best assess the quality of life of people with dementia? the Bath Assessment of Subjective Quality of Life in Dementia (BASQID)Richard Trigg, Suzanne M Skevington, Roy W Jones
Pageof 9